AstraZeneca updates on olaparib and TC-5214 development programmes

Tuesday, 20 December 2011

With associated impairment charges, company confirms full year financial target, but guides to lower half of its Core EPS range

AstraZeneca today announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point. As a result, AstraZeneca will take pre-tax impairment charges totalling $381.5 million to R&D expense in the fourth quarter of 2011. The company confirms its expectation for full year Core EPS in the range of $7.20 to $7.40, but with the inclusion of these intangible impairments, Core EPS is likely to be in the lower half of this range.

View full press release

“As a science-led organisation, we trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.”

Pascal Soriot
Chief Executive Officer

Download our brochure

Download your comprehensive guide to partnering with us.

Partnering news

AstraZeneca and Cambridge Judge Business School announce collaboration to identify and support biotech start-ups
3 March 2015
AstraZeneca wins three business development awards at 10th Annual Scrip Awards 2014
8 December 2014
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
16 September 2014
AstraZeneca agrees strategic transaction with Almirall in respiratory disease
30 July 2014
AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study
30 July 2014
New drug active against most aggressive type of lung cancer cells
10 July 2014
MRC Technology and AstraZeneca Renew Collaboration to Identify Novel Targets for Discovery Research
3 July 2014
AstraZeneca in-licenses Synairgen’s SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma
12 June 2014
MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial
14 May 2014
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance
3 February 2014
AstraZeneca provides update at JP Morgan Healthcare Conference on progress to achieve scientific leadership and return to growth
14 January 2014
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
8 January 2014
AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR®
26 December 2013
AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets
19 December 2013
AstraZeneca wins two Scrip Awards
22 November 2013
AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
15 October 2013
AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
11 October 2013
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
11 September 2013
MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
26 August 2013
AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease
31 July 2013
AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research
9 July 2013
AstraZeneca Completes Acquisition Of Pearl Therapeutics
28 June 2013
MedImmune, AstraZeneca’s biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity
17 June 2013
AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
10 June 2013
AstraZeneca to acquire Omthera Pharmaceuticals including NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio
28 May 2013
AstraZeneca and MedImmune are out in force at BIO 2013
1 May 2013
Alchemia Announces Multi-Target Drug Discovery Collaboration with AstraZeneca on VAST Discovery Platform
24 April 2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca
22 April 2013
AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine
22 April 2013
MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma
3 April 2013
AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy
21 March 2013
AstraZeneca and Karolinska Institutet to create Integrated Translational Research Centre
21 March 2013
AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer
21 March 2013
AstraZeneca announces changes to Senior Executive Team
15 January 2013
AstraZeneca and Vanderbilt University collaborate to develop novel treatments for major brain disorders
14 January 2013
Kicking off 2013 with strong presence at 31st annual JPMorgan event
9 January 2013
CytImmune and AstraZeneca to Research Potential New Nanomedicine
27 December 2012
AstraZeneca and LegoChem Biosciences announce collaboration on treatment of antibiotic-resistant bacterial infections
20 December 2012
AstraZeneca and Fudan University sign research collaboration in China
18 December 2012
AstraZeneca and Isis Pharmaceuticals form strategic alliance on RNA therapeutics for cancer
11 December 2012
AstraZeneca wins Scrip Award for “Best Partnership Alliance” for third consecutive year
29 November 2012
Alzheimer’s, cancer and rare disease research to benefit from landmark MRC-AstraZeneca compound collaboration
31 October 2012
AstraZeneca and Ironwood announce linaclotide collaboration for China
23 October 2012
AstraZeneca and Ardelyx announce worldwide licensing deal for NHE3 Inhibitor Programme for complications of renal disease, including diabetes-induced renal disease
8 October 2012
AstraZeneca collaborates with Roche Diagnostics to advance personalised healthcare across therapeutic areas
26 September 2012
AstraZeneca wins prestigious business development award
12 September 2012
AstraZeneca and Pfizer enter agreement for over-the-counter NEXIUM; AstraZeneca raises 2012 guidance
13 August 2012
AstraZeneca and Bristol-Myers Squibb complete expansion of diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals
9 August 2012
AstraZeneca acquires neuroscience assets from Link Medicine
12 July 2012
AstraZeneca and leading academic scientists to collaborate on Alzheimer's disease research
12 July 2012
Bristol-Myers Squibb and AstraZeneca expand diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals
30 June 2012
Innovative public-private collaboration launches to tackle antibiotic research
24 May 2012
AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout  
23 April 2012
Conformetrix and AstraZeneca sign collaborative agreement
16 April 2012
AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio
2 April 2012
BioFocus and Argenta announce drug discovery collaboration with AstraZeneca in respiratory and inflammatory disease
14 March 2012
AstraZeneca Appoints Dr. Mike Poole to Lead New ‘Virtual’ Neuroscience Innovative Medicines Unit
7 February 2012
AstraZeneca and Karolinska Institutet PET Centre Announce Molecular Imaging Research Agreement
26 January 2012
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe
11 January 2012
Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease
5 January 2012
Dynavax and AstraZeneca agree to conduct toxicology studies for TLR-9 agonist for asthma
21 December 2011
AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion
21 December 2011
AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy
21 December 2011
AstraZeneca updates on olaparib and TC-5214 development programmes
20 December 2011
Enlight Biosciences forms new partnerships with AstraZeneca and Novo Nordisk
15 December 2011
AstraZeneca out-licenses imaging agent for amyloid detection to aid diagnosis of Alzheimer’s disease to Neoprobe
13 December 2011
AstraZeneca to acquire generics company to broaden patient access to medicines in China
8 December 2011
Groundbreaking scientific collaboration gives UK academia access to compounds to advance medical research
5 December 2011
AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures
28 November 2011
AstraZeneca and Forest Laboratories to initiate phase III clinical trials for ceftazidime/avibactam to treat serious Gram-negative bacterial infections
18 November 2011
AstraZeneca and Targacept announce first top-line Phase III results for TC-5214 as an adjunct treatment in patients with major depressive disorder
8 November 2011
AstraZeneca Wins Scrip Award for “Best Partnership Alliance”
4 November 2011
BioPartnering Europe, London, October 2011
25 October 2011
AstraZeneca and Forest Laboratories to initiate phase III clinical trials for ceftazidime/avibactam to treat serious Gram-negative bacterial infections
18 October 2011
MedImmune in-licenses cancer immunotherapy tremelimumab from Pfizer
3 October 2011
Cancer Research Technology and Cancer Research UK establish lipid metabolism research team
29 September 2011
AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration with potential extension to other therapeutic areas
29 June 2011
AstraZeneca signs agreement in Japan with Daiichi Sankyo to co-promote denosumab for cancer
24 May 2011
AstraZeneca and HealthCore Announce Real-World Evidence Data Collaboration in the US
2 February 2011
Strategic Collaboration to Develop Innovative Drug Therapies
11 January 2011
MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody from AMGEN. Antibody Targeting IL-1 Receptor Further Strengthens Inflammatory Disease Pipeline
7 January 2011